Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-23T21:46:33.513Z Has data issue: false hasContentIssue false

Chapter 36 - Hematological Malignancies in Pregnancy (Content last reviewed: 14th December 2020)

from Section 5 - Late Pregnancy – Maternal Problems

Published online by Cambridge University Press:  15 November 2017

By
David Allsup ,
Abubaker Ibnouf ,
Sahra Ali  and
Susan Robinson
Edited by
David James ,
Philip Steer ,
Carl Weiner ,
Bernard Gonik  and
Stephen Robson
David James
Affiliation:
University of Nottingham
Philip Steer
Affiliation:
Imperial College London
Carl Weiner
Affiliation:
University of Kansas
Bernard Gonik
Affiliation:
Wayne State University, Detroit
Stephen Robson
Affiliation:
University of Newcastle
Get access

Summary

The diagnosis of a hematological malignancy during pregnancy poses a major challenge to the pregnant woman, her family, and the medical team. Treatment of a pregnant woman with chemotherapy poses a risk to the fetus and raises therapeutic, ethical, and social dilemmas. A woman diagnosed with a hematological malignancy during pregnancy should be managed jointly by a multidisciplinary team comprising consultant hematologist, obstetrician, midwife, anesthesiologist, and neonatologist. Consideration should be given to the health of both mother and baby, with the informed wishes of the mother being considered paramount by the medical team. Psychological support should be offered to the woman and her family. Information giving should be supported by written information and a treatment plan. The woman should be fully informed about the diagnosis, her treatment options, potential complications, and the possible fetal and maternal outcomes.

Type
Chapter
Information
High-Risk Pregnancy
Management Options
 , pp. 1005 - 1042
Publisher: Cambridge University Press
First published in: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Further Reading: Web Resources

A video produced by the University of Leicester, UK, demonstrating BMB. https://youtu.be/svTQ-zJHY9M.Google Scholar
Patient information regarding hematological cancers and their treatment, produced by the charity Macmillan. www.macmillan.org.uk.Google Scholar
Patient information specific to hematological cancers produced by the charity Bloodcancer UK. bloodcancer.org.uk.Google Scholar
Information for healthcare professionals and patients produced by the American Society of Hematology. www.hematology.org.Google Scholar
Information for professionals produced by the British Society for Haematology. www.b-s-h.org.uk.Google Scholar
Information on a broad range of conditions including hematological disorders produced by the UK National Health Service. www.nhs.uk.Google Scholar
Data on incidence, age at diagnosis, and outcomes for hematological malignancies diagnosed within Yorkshire and Humberside, United Kingdom, from the Haematological Malignancy Research Network (HMRN). www.hmrn.org.Google Scholar

References

Stone, RM, Mandrekar, SJ, Sanford, BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017; 377: 454–64. doi: 10.1056/NEJMoa1614359.Google Scholar
Lancet, JE, Uy, GL, Cortes, JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018; 36: 2684–92. https://doi.org/10.1200/JCO.2017.77.6112.Google Scholar
Döhner, H, Estey, E, Grimwade, D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 424–47. https://doi.org/10.1182/blood-2016-08-733196.Google Scholar
Lambert, J, Pautas, C, Terré, C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 2019; 104: 113–19. https://doi.org/10.3324/haematol.2018.188888.Google Scholar
Killick, SB, Carter, C, Culligan, D, et al.; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol 2014; 164: 503–25. https://doi.org/10.1111/bjh.12694.Google Scholar
Fenaux, P, Giagounidis, A, Selleslag, D, et al.; MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765–76. https://doi.org/10.1182/blood-2011-01-330126.Google Scholar
Yazji, S, Giles, FJ, Tsimberidou, AM, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003; 17: 2101–6. https://doi.org/10.1038/sj.leu.2403124.Google Scholar
McMullin, MF, Harrison, CN, Ali, S, et al.; BSH Committee. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. Br J Haematol 2019; 184: 176–91. https://doi.org/10.1111/bjh.15648. Erratum in: Br J Haematol 2019; 185: 198.Google Scholar
Vannucchi, AM, Kiladjian, JJ, Griesshammer, M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015; 372: 426–35. https://doi.org/10.1056/NEJMoa1409002.CrossRefGoogle ScholarPubMed
Marcus, R, Davies, A, Ando, K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017; 377: 1331–44. https://doi.org/10.1056/NEJMoa1614598.Google Scholar
Woyach, JA, Ruppert, AS, Heerema, NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018; 379: 2517–28. https://doi.org/10.1056/NEJMoa1812836.Google Scholar
Morgan, GJ, Davies, FE, Gregory, WM, et al.; NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011; 118: 1231–8. https://doi.org/10.1182/blood-2011-02-338665.Google Scholar
Hurley, TJ, McKinnell, JV, Irani, MS. Hematologic malignancies in pregnancy. Obstet Gynecol Clini North Am 2005; 32: 595–614.Google Scholar
Ali, S, Jones, GL, Culligan, DJ, et al. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Br J Haematol 2015; 170: 487–95. doi: 10.1111/bjh.13554.Google Scholar
Horowitz, NA, Henig, I, Henig, O, et al. Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis. Leuk Lymphoma 2018; 59: 610–16. doi: 10.1080/10428194.2017.1347651.CrossRefGoogle ScholarPubMed
Farhadfar, N, Cerquozzi, S, Hessenauer, MR, et al. Acute leukemia in pregnancy: a single institution experience with 23 patients. Leuk Lymphoma 2017; 58: 1052–60. doi: 10.1080/10428194.2016.1222379.Google Scholar
Amant, F, Han, SN, Gziri, MM, Dekrem, J, Van Calsteren, K. Chemotherapy during pregnancy. Curr Opin Oncol 2012; 24: 580–6.Google Scholar
Greenlund, LJ, Letendre, L, Tefferi, A. Acute leukemia during pregnancy: a single institutional experience with 17 cases. Leuk Lymphoma 2001; 41: 571–7.Google Scholar
Cardonick, E, Iacobucci, A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5: 283–91.Google Scholar
Reynoso, EE, Shepherd, FA, Messner, HA, et al. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol 1987; 5: 1098–106.Google Scholar
Chelghoum, Y, Vey, N, Raffoux, E, et al. Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer 2005; 104: 110–17.Google Scholar
Shapira, T, Pereg, D, Lishner, M. How I treat acute and chronic leukemia in pregnancy. Blood Rev 2008; 22: 247–59.CrossRefGoogle Scholar
Moorman, AV, Harrison, CJ, Buck, GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189–97.Google Scholar
Lin A, Zhou Q, Devlin S, Adel NG, Douer D. Outcomes of tyrosine kinase inhibitors in combination with various treatments regimens in adult patients with philadelphia chromosome positive acute lymphocytic leukemia. Blood 2013; 122: 2644. https://doi.org/10.1182/blood.V122.21.2644.2644.Google Scholar
Fielding, AK, Rowe, JM, Buck, G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014; 123: 843–50.Google Scholar
Breccia, M, Mengarelli, A, Mancini, M, et al. Myelodysplastic syndromes in patients under 50 years old: a single institution experience. Leuk Res 2005; 29: 749–54.Google Scholar
Ikeda, Y, Masuzaki, H, Nakayama, D, et al. Successful management and perinatal outcome of pregnancy complicated with myelodysplastic syndrome. Leuk Res 2002; 26: 255–60.CrossRefGoogle ScholarPubMed
Siddiqui, T, Elfenbein, GJ, Noyes, WD, et al. Myelodysplastic syndromes presenting in pregnancy: a report of five cases and the clinical outcome. Cancer 1990; 66: 377–81.Google Scholar
Fadilah, SA, Roswati, MN. Refractory anaemia with excess of blasts in transformation (RAEB-T) during pregnancy with haematological remission following delivery. Br J Haematol 1999; 104: 935–6.Google Scholar
Essien, EM, Sharma, U, Upadhaya, K, Malik, R. Myelodysplastic syndrome and successful pregnancy. Int J Hematol 1998; 68: 449–52.Google Scholar
Yang Z, Mei-Ying L, Shan-Mi W, Xiao-Hui Z. Pregnancy and myelodysplastic syndrome: an analysis of the clinical characteristics, maternal and fetal outcomes. J Matern Fetal Neonatal Med 2015; 28: 2155–9. https://doi.org/10.3109/14767058.2014.980229.Google Scholar
Volpicelli P, Latagliata R, Breccia M, et al. Pregnancy in patients with myelodysplastic syndromes (MDS). Leuk Res 2008; 32: 1605–7. https://doi.org/10.1016/j.leukres.2008.02.006.Google Scholar
Hellström-Lindberg, E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67–71.Google Scholar
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–405. https://doi.org/10.1182/blood-2016-03-643544.Google Scholar
Robinson, S, Bewley, S, Hunt, BJ, Radia, DH, Harrison, CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica 2005; 90: 1477–83.Google Scholar
Tulpule, S, Bewley, S, Robinson, SE, et al. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br J Haematol 2008; 142: 480–2.Google Scholar
Valera, MC, Parant, O, Vayssiere, C, Arnal, JF, Payrastre, B. Essential thrombocythemia and pregnancy. Eur J Obstet Gynecol Reprod Biol 2011; 158: 141–7.Google Scholar
Barbui, T, Finazzi, G. Myeloproliferative disease in pregnancy and other management issues. Hematology Am Soc Hematol Educ Program 2006: 246–52.Google Scholar
Alimam, S, Bewley, S, Chappell, LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol 2016; 175: 31–6.Google Scholar
CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343: 619–29.Google Scholar
Gangat, N, Wolanskyj, AP, Schwager, S, Tefferi, A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 2009; 82: 350–3.Google Scholar
Cnossen, JS, Morris, RK, ter Riet, G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008; 178: 701–11.Google Scholar
Llurba, E, Carreras, E, Gratacos, E, et al. Maternal history and uterine artery Doppler in the assessment of risk for development of early- and late-onset preeclampsia and intrauterine growth restriction. Obstet Gynecol Int 2009; 2009: 275613.Google Scholar
Willoughby, SJ, Fairhead, S, Woodcock, BE, Pearson, TC. Postpartum thrombosis in primary thrombocythaemia. Eur J Haematol 1997; 59: 121–3.CrossRefGoogle ScholarPubMed
Ware RE, Marahatta A, Ware JL, McElhinney K, Dong M, Vinks AA. Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). J Pediatr 2020; 222: 236–9. https://doi.org/10.1016/j.jpeds.2020.02.002.Google Scholar
Robinson SE, Harrison CN. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. Br J Haematol 2020; 189: 625–34. https://doi.org/10.1111/bjh.16453.Google Scholar
Griesshammer, M, Sadjadian, P, Wille, K. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol 2018; 11: 697–706. doi: 10.1080/17474086.2018.1506325.Google Scholar
Kantarjian, H, Sawyers, C, Hochhaus, A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–52.Google Scholar
Druker, BJ, Guilhot, F, O’Brien, SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–17.Google Scholar
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34: 966–84. https://doi.org/10.1038/s41375-020-0776-2.Google Scholar
Pye, SM, Cortes, J, Ault, P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111: 5505–8.Google Scholar
Mahon, FX, Rea, D, Guilhot, J, et al.; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–35.Google Scholar
Goh, HG, Kim, YJ, Kim, DW, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 2009; 50: 944–51.Google Scholar
Lasica, M, Willcox, A, Burbury, K, et al. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma 2019; 60: 1796–802. doi: 10.1080/10428194.2018.1551533.Google Scholar
Muller, AM, Ihorst, G, Mertelsmann, R, Engelhardt, M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84: 1–12.Google Scholar
Health Protection Agency, Royal College of Radiologists, College of Radiographers. Protection of Pregnant Patients during Diagnostic Medical Exposures to Ionising Radiation. London: HPA, RCR, CoR, 2009. https://www.rcr.ac.uk/protection-pregnant-patients-during-diagnostic-medical-exposures-ionising-radiation (accessed March 2017).Google Scholar
Takalkar AM, Khandelwal A, Lokitz S, Lilien DL, Stabin MG. 18F-FDG PET in pregnancy and fetal radiation dose estimates. J Nucl Med 2011; 52: 1035–40. https://doi.org/10.2967/jnumed.110.085381.Google Scholar
American College of Obstetricians and Gynecologists. Committee Opinion No. 723. Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol 2017; 130: e210–16. doi: 10.1097/AOG.0000000000002355.Google Scholar
Medicines and Healthcare Products Regulatory Agency. Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical Use. London: MHRA, 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/476931/MRI_guidance_2015_-_4-02d1.pdf (accessed March 2017).Google Scholar
Webb, JA, Thomsen, HS, Morcos, SK; Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 2005; 15: 1234–40.Google Scholar
Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 2013; 132: e796–809. https://doi.org/10.1542/peds.2013-1985.Google Scholar
Cheson, BD, Fisher, RI, Barrington, SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059–68.Google Scholar
Gleissner, B, Kuppers, R, Siebert, R, et al. Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. Br J Haematol 2008; 142: 166–78.Google Scholar
Hasenclever, D, Diehl, V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339: 1506–14.Google Scholar
Mead, GM, Barrans, SL, Qian, W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 2248–60.Google Scholar
Pinnix, CC, Osborne, EM, Chihara, D, et al. Maternal and fetal outcomes after therapy for hodgkin or non-hodgkin lymphoma diagnosed during pregnancy. JAMA Oncol 2016; 2: 1065–9. doi: 10.1001/jamaoncol.2016.1396.Google Scholar
Evens, AM, Advani, R, Press, OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol 2013; 31: 4132–9.Google Scholar
Stark, D, Lewis, I. Improving outcomes for teenagers and young adults (TYA) with cancer. Klin Padiatr 2013; 225: 331–4.Google Scholar
Reich, EW, Cox, RP, Becker, MH, et al. Recognition in adult patients of malformations induced by folic-acid antagonists. Birth Defects Orig Artic Ser 1978; 14: 139–60.Google Scholar
Sarno, MA, Mancari, R, Azim, HA, Colombo, N, Peccatori, FA. Are monoclonal antibodies a safe treatment for cancer during pregnancy? Immunotherapy 2013; 5: 733–41.Google Scholar
Chakravarty, EF, Murray, ER, Kelman, A, Farmer, P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011; 117: 1499–506.Google Scholar
de Wildt, SN, Taguchi, N, Koren, G. Unintended pregnancy during radiotherapy for cancer. Nat Clin Pract Oncol 2009; 6: 175–8.Google Scholar
Pinnix CC, Osborne EM, Chihara D, et al. Maternal and fetal outcomes after therapy for Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy. JAMA Oncol 2016; 2: 1065–9. https://doi.org/10.1001/jamaoncol.2016.1396.Google Scholar
Evens AM, Advani R, Losso IS. Lymphoma in pregnancy: excellent fetal outcomes and maternal survival in a large multicenter analysis. Blood 2011; 118: 94. https://doi.org/10.1182/blood.V118.21.94.94.Google Scholar
Barton, S, Hawkes, EA, Wotherspoon, A, Cunningham, D. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? Oncologist 2012; 17: 1562–73.Google Scholar
Zhou, Z, Sehn, LH, Rademaker, AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123: 837–42.Google Scholar
Boyle, J, Beaven, AW, Diehl, LF, Prosnitz, LR, Kelsey, CR. Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy. Oncology (Williston Park) 2014; 28: 1074–81, 1084.Google Scholar
Pregno, P, Chiappella, A, Bello, M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012; 119: 2066–73.Google Scholar
Viviani, S, Zinzani, PL, Rambaldi, A, et al.; Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365: 203–12.Google Scholar
Follows, GA, Ardeshna, KM, Barrington, SF, et al.; British Committee for Standards in Haematology. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol 2014; 166: 34–49.Google Scholar
Dearden, CE, Johnson, R, Pettengell, R, et al.; British Committee for Standards in Haematology. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153: 451–85.Google Scholar
Ribera, JM, Garcia, O, Grande, C, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer 2013; 119: 1660–8.Google Scholar
Perkins, AS, Friedberg, JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program 2008; 2008: 341–8.Google Scholar
Peterson, C, Lester, DR, Sanger, W. Burkitt’s lymphoma in early pregnancy. J Clin Oncol 2010; 28: e136–8.Google Scholar
Middeke, JM, Bruck, N, Parmentier, S, Bornhauser, M, Schetelig, J. Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome. Ann Hematol 2014; 93: 531–2.Google Scholar
McNamara, C, Davies, J, Dyer, M, et al.; Haemato-oncology Task Force of the British Committee for Standards in Haematology, British Society for Haematology Committee. Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 2012; 156: 446–67.Google Scholar
McKay, P, Leach, M, Jackson, R, Cook, G, Rule, S; British Committee for Standards in Haematology. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 2012; 159: 405–26.Google Scholar
Kluin-Nelemans, HC, Hoster, E, Hermine, O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520–31.Google Scholar
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5.Google Scholar
Jurczyszyn A, Olszewska-Szopa M, Vesole AS, et al. Multiple myeloma in pregnancy: a review of the literature and a case series. Clin Lymphoma Myeloma Leuk 2016 Mar; 16(3): e39–45. https://doi.org/10.1016/j.clml.2015.11.020.Google Scholar
Green, SB, Pappas, AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm 2014; 71: 2029–36.Google Scholar
Hamad, N, Kliman, D, Best, OG, et al. Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management. Br J Haematol 2015; 168: 350–60.Google Scholar
Itala, M, Geisler, CH, Kimby, E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002; 69: 129–34.Google Scholar
Einarson, A, Maltepe, C, Navioz, Y, et al. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004; 111: 940–3.Google Scholar
King, CT, Rogers, PD, Cleary, JD, Chapman, SW. Antifungal therapy during pregnancy. Clin Infect Dis 1998; 27: 1151–60.Google Scholar
Boxer LA, Bolyard AA, Kelley ML, et al. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. Obstet Gynecol 2015; 125: 197–203. https://doi.org/10.1097/AOG.0000000000000602.Google Scholar
Sanchez-Gonzalez LR, Castro-Melendez SE, Angeles-Torres AC, et al. Efficacy and safety of adjuvant recombinant human erythropoietin and ferrous sulfate as treatment for iron deficiency anemia during the third trimester of pregnancy. Eur J Obstet Gynecol Reprod Biol 2016; 205: 32–6. https://doi.org/10.1016/j.ejogrb.2016.08.004. Epub 2016 Aug 10. PMID: 27566219.Google Scholar
Royal College of Obstetricians and Gynaecologists. Antenatal Corticosteroids to Reduce Neonatal Morbidity. Green-top Guideline No. 7. London: RCOG, 2010. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg7 (accessed March 2017).Google Scholar
Royal College of Obstetricians and Gynaecologists. Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth. Scientific Impact Paper No. 29. London: RCOG, 2011. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/sip29 (accessed March 2017)Google Scholar
Qureshi, H, Massey, E, Kirwan, D, et al.; British Society for Haematology. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med 2014; 24: 8–20.Google Scholar
US National Library of Medicine. Drugs and Lactation Database (LactMed). https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm (accessed March 2017).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×